combination

Enanta Pharmaceuticals CEO Jay Luly
Biotech

Enanta pulls plug on NASH, seeks to offload assets for combos

After getting a look at interim phase 2b data, the biotech has decided to stop the monotherapy trial and seek to outlicense its candidates.
Nick Paul Taylor Oct 4, 2021 8:40am
PILLS MONEY cost opioid

Otsuka and Proteus sign 5-year, $88M digital pill partnership

Oct 11, 2018 10:33am
FDA

FDA could end 'confusing and inefficient' drug-device process

May 16, 2018 8:45am
Pfizer HQ

Pfizer culls 5 experimental cancer trials in Q1 clear out

May 1, 2018 9:26am
Mercks site in Upper Gwynedd PA

Merck inks $394M takeover of oncolytic virus play Viralytics

Feb 21, 2018 5:39am
FDA

Otsuka, Proteus refile for FDA approval of digital medicine

May 24, 2017 9:50am